1,729 件 ・ 関連度順
概要と使いどころ
Create and maintain agent skills with concise trigger metadata, judgement-aware guidance, progressive disclosure, and tested interfaces. Use when adding, refactoring, reviewing, or troubleshooting skills and their bundled scripts or references.
日本語の概要は準備中です。原文の説明を表示しています。
Establish concise, cross-agent project instructions from repository evidence. Use when initializing or repairing AGENTS.md, CLAUDE.md, related discovery links, or project-specific agent guidance.
日本語の概要は準備中です。原文の説明を表示しています。
Translate text accurately between languages with pronunciation guidance for non-Latin scripts.
日本語の概要は準備中です。原文の説明を表示しています。
Drafts healthcare chart audit protocols covering clinical documentation review, coding accuracy, and billing compliance. Aligns with Medicare CoPs, OIG Compliance Program Guidance, RAC preparedness, federal sentencing guidelines, and the 60-day overpayment rule. Use when drafting routine periodic audits, targeted risk reviews, proactive compliance measures, or post-regulatory-update assessments.
日本語の概要は準備中です。原文の説明を表示しています。
Generates structured U.S. art law summaries with Bluebook citations, doctrinal analysis, and stakeholder guidance. Use when researching art law precedents, advising on art transactions, preparing for art market litigation, or surveying a doctrine or statute across ownership, provenance, copyright, VARA, NAGPRA, authentication, NFTs, or AI-generated art.
日本語の概要は準備中です。原文の説明を表示しています。
Comprehensive legal applications skill covering civil/criminal/administrative litigation workflows, trial defense strategies, legal document drafting (complaints, answers, appeals, retrial petitions, enforcement applications, representation opinions, defense statements, legal opinions, etc.), arbitration (commercial & labor), mediation, enforcement procedures, evidence rules, and litigation risk assessment. Trigger when users ask about: lawsuit/litigation/trial, legal documents, court defense, evidence/cross-examination, arbitration, enforcement, legal strategy, filing a case, appeal, retrial, representation, pleading, or any legal procedural guidance.
日本語の概要は準備中です。原文の説明を表示しています。
Create aesthetically beautiful interfaces following proven design principles. Use when building UI/UX, analyzing designs from inspiration sites, generating design images with ai-multimodal, implementing visual hierarchy and color theory, adding micro-interactions, or creating design documentation. Includes workflows for capturing and analyzing inspiration screenshots with chrome-devtools and ai-multimodal, iterative design image generation until aesthetic standards are met, and comprehensive design system guidance covering BEAUTIFUL (aesthetic principles), RIGHT (functionality/accessibility), SATISFYING (micro-interactions), and PEAK (storytelling) stages. Integrates with chrome-devtools, ai-multimodal, media-processing, ui-styling, and web-frameworks skills.
日本語の概要は準備中です。原文の説明を表示しています。
Bridge Codex to web-based AI model products by packaging local task context, scrub-checking it, sending it through an approved browser surface to ChatGPT Pro, Claude, Grok, Gemini, or another web model, waiting for the answer, and returning the model response to the user or Codex. Also guide DevSpace-like MCP Connector Mode when the user wants ChatGPT Pro or another MCP-capable web host to access approved local workspaces without relying on Codex browser automation. Use when the user asks for GPT Pro, ChatGPT Pro, Claude web, Grok, Gemini web, web model bridge, external model consult, ask another model, second opinion, use a web AI model, browserless agent access to GPT Pro, MCP connector, DevSpace-like workflow, or send local repo context to a browser-based model for planning, review, debugging, architecture discussion, or implementation guidance.
日本語の概要は準備中です。原文の説明を表示しています。
This skill should be used when the user asks to "create a plugin", "scaffold a plugin", "understand plugin structure", "organize plugin components", "set up plugin.json", "use ${CLAUDE_PLUGIN_ROOT}", "add commands/agents/skills/hooks", "configure auto-discovery", or needs guidance on plugin directory layout, manifest configuration, component organization, file naming conventions, or Claude Code plugin architecture best practices.
日本語の概要は準備中です。原文の説明を表示しています。
Pragmatic testing guidance focused on confidence, behavior over implementation details, and integration-first coverage. Use when designing a test strategy, writing or reviewing tests, reducing brittle mocks, or deciding what is worth testing in an application or library.
日本語の概要は準備中です。原文の説明を表示しています。
Compassionate bereavement support, memorial creation, grief education, and healing journey guidance. Specializes in understanding grief stages, creating meaningful tributes, and supporting the non-linear path of loss.
日本語の概要は準備中です。原文の説明を表示しています。
Performs root cause analysis on DAG execution failures. Traces failure propagation, identifies systemic issues, and generates actionable remediation guidance. Activate on 'failure analysis', 'root cause', 'why did it fail', 'debug failure', 'error investigation'. NOT for execution tracing (use dag-execution-tracer) or performance issues (use dag-performance-profiler).
日本語の概要は準備中です。原文の説明を表示しています。
Strategic analyst that maps competitive landscapes, identifies white space opportunities, and provides positioning recommendations. Use when users need competitive analysis, market positioning strategy, differentiation tactics, or "how do I stand out?" guidance across any domain (portfolios, products, services). NOT for market size estimation or financial forecasting.
日本語の概要は準備中です。原文の説明を表示しています。
Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CUT&RUN (Skene Henikoff 2017) and CUT&Tag (Kaya-Okur 2019) chromatin profiling data. Handles SEACR vs MACS2 peak calling (with the btaf375 2025 benchmark guidance), pA-MNase vs pA-Tn5 vs pAG-Tn5 chimera differences, E. coli spike-in carryover normalization, IgG-only control logic (no input), characteristic fragment-size signatures (25-75 bp for CUT&Tag), and lower depth requirements (5M reads typical vs 25M for ChIP). Use when calling peaks from CUT&RUN/CUT&Tag, scaling by E. coli spike-in carryover, choosing SEACR norm mode, or comparing CUT&RUN/Tag results to traditional ChIP.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
日本語の概要は準備中です。原文の説明を表示しています。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Guidance for SPR and BLI binding characterization experiments. Use when: (1) Planning binding kinetics experiments, (2) Troubleshooting poor/no binding signal, (3) Interpreting kinetic data artifacts, (4) Choosing between SPR vs BLI platforms.
日本語の概要は準備中です。原文の説明を表示しています。
Trim multiple sequence alignments using ClipKIT, trimAl, BMGE, Divvier, or HMMcleaner with mode selection guidance per downstream goal. Use when removing unreliable columns or contaminating residues before phylogenetic inference, HMM building, or selection analysis.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end binder design using BindCraft hallucination. Use this skill when: (1) Designing protein binders with built-in AF2 validation, (2) Running production-quality binder campaigns, (3) Using different design protocols (fast, default, slow), (4) Need joint backbone and sequence optimization, (5) Want high experimental success rate. For backbone-only generation, use rfdiffusion. For QC thresholds, use protein-qc. For tool selection guidance, use binder-design.
日本語の概要は準備中です。原文の説明を表示しています。